Spiriva Sales Data

Rank 13 Current sales rank, all
U.S. Pharmaceuticals.

Last updated: February 2014 (updated quarterly).
The following data shows Spiriva U.S. retail sales in Q4 2013 compared to previous quarters.

Date Range Sales Rank Sales ($000) Units (000)
Q4 2013 13 -0.16% -9.61%
Q3 2013 13 (1) 3.45% -7.14%
Q2 2013 12 -0.42% 0.89%
Q1 2013 12 3.39% -1.50%
Q4 2012 12 (2) 4.83% 5.56%
Q3 2012 14 (3) 1.31% 1.34%
Q2 2012 17 (2) 0.21% 0.76%
Q1 2012 19 (3) 8.12% 5.62%
Q4 2011 22 (1) 6.93% 2.48%
Q3 2011 23 -1.46% -2.45%
Q2 2011 23 3.82% 2.29%
Q1 2011 23

* Units refer to the number of packages sold.

Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.

Related News

DateArticle
June 14, 2011COPD Drug Via Mist Inhaler Could Raise Death Risk: Study
March 23, 2011For Lung Disorder, Spiriva Beat Serevent in Head-to-Head Trial
September 19, 2010Early Trial Suggests COPD Drug Might Help Some Asthmatics
January 14, 2010Leading COPD Drug Won't Harm Heart: FDA
November 19, 2009FDA Panel Backs Safety, Benefits of Spiriva
October 5, 2008Spiriva Safe, Effective for COPD Patients
September 23, 2008Leading COPD Drugs Tied to Stroke, Heart Attack
Hide
(web3)